FDA Brief

Warning letters Drugs

FDA warning letter to

Shantou S.E.Z. Baojie Industry Co., Ltd.

High riskIssued Apr 15, 2025Posted May 13, 2025Center for Drug Evaluation and Research (CDER)

FDA warns Shantou S.E.Z. Baojie Industry over inadequate CGMP and component testing for OTC drug products, leading to Import Alert 66-40.

What happened

FDA inspected the Shantou, Guangdong, China drug manufacturing facility from August 26 to 30, 2024. The inspection found inadequate identity and conformity testing of incoming components, including components at higher risk of contamination, despite a prior commitment to test every lot, plus inadequate production controls, stability testing, and quality-unit oversight. FDA placed products offered for import from the firm on Import Alert 66-40 on April 9, 2025.

What FDA found

  1. The firm did not test each incoming component lot for identity and conformity and relied on supplier certificates without validating the suppliers’ test results.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  2. The firm lacked adequate written production and process controls for a system it uses as a drug component and for cleaning equipment, with insufficient validation and monitoring.

    21 CFR 211.100(a)
  3. The firm’s stability program was inadequate because it used only odor, color, and appearance checks and lacked chemical and microbial testing to support labeled expiration dates.

    21 CFR 211.166(a)
  4. The quality control unit failed to oversee incoming component testing, production procedures, stability testing, product reviews, and test-method verification.

    21 CFR 211.22

What FDA wants

FDA tells the firm to respond in writing within 15 working days with corrective actions and supporting data, including high-risk component test results within 30 calendar days, a risk assessment for products within expiry, and remediation plans for the system, stability program, and quality unit. If it intends to resume U.S. manufacturing, FDA recommends a qualified CGMP consultant.

Who should pay attention

  • U.S. distributors and brands selling OTC drug products made by this firm
  • drug manufacturers that buy high-risk components or rely on supplier test reports
  • quality teams responsible for incoming component testing and supplier qualification

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk